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P U B L I S H E D B Y E L S E V I E R I N C .LettersIn Regard to the
TERISA TrialI read with great interest the paper by Kosiborod et al.
(1) showing beneﬁcial effects of ranolazine in patients
with type 2 diabetes mellitus, coronary artery disease,
and chronic refractory angina taking 2 antianginal
agents. The authors demonstrate superior efﬁcacy of
ranolazine in reducing weekly anginal episodes, as
well as weekly nitroglycerin use in this patient
population.
The study design raises few important questions:
First, >50% of the patients in the study were not
taking two antianginal medications. Given the sys-
tolic blood pressure of >130 mm Hg in both of the
groups at the beginning of the study and the fact that
approximately only 34% of patients in each group
were taking nitrate therapy prior to enrollment, it
would be beneﬁcial to know the doses of long-acting
nitrates in these patients as there was adequate
room to up-titrate the nitrate therapy and the pa-
tients were not truly refractory to 2 antianginal
medications. Second, it would be important for the
readers to know whether the beneﬁcial effect of
ranolazine was extended for the duration of angina as
well as the ischemic burden in this patient group (as
assessed objectively by means of Holter electrocar-
diogram or other cardiac monitoring devices).
Third, a previous subgroup analysis from a trial of
ranolazine (2) showed that the effect of reduction in
A1c was greater in diabetic patients taking insulin
than in those not taking insulin therapy. Again, it
would be interesting to see if those results are repli-
cable in the TERISA trial study population.*Harsh Golwala, MD
University of Oklahoma Health Sciences Center
Williams Pavilion, 1130
P. O. Box 26901
Oklahoma City, Oklahoma 73190
E-mail: Harsh-golwala@ouhsc.edu
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2006;27:42–8.REPLY: In Regard to the TERISA TrialDr. Golwala raises several questions in regard to the
TERISA trial (1). First is whether the patients enrolled
in TERISA were truly refractory to maximally titrated
baseline antianginal treatment at randomization.
The protocol did not require titration of baseline
antianginal drugs to maximum approved or tolerated
doses because the objective of TERISA was not to
evaluate the effects of ranolazine added to maxi-
mized treatment but rather to assess ranolazine’s
effectiveness against placebo as add-on therapy for
patients with type 2 diabetes (T2DM) who had resid-
ual angina despite being treated with one or two
other antianginal agents.
The second point raised is whether the beneﬁcial
effect of ranolazine extended beyond angina fre-
quency, speciﬁcally whether data were available for
angina duration and ischemic burden as evaluated
using Holter electrocardiographic monitoring. No
such monitoring of ischemic burden or angina
duration was performed in TERISA. We feel that
frequency of patient-reported angina and use of
sublingual nitroglycerine are more clinically mean-
ingful to individual patients and their treating
physicians than “harder” endpoints such as
ischemic changes on a treadmill protocol or Holter
monitoring. The clinical effectiveness of an anti-
anginal agent in clinical practice would typically be
assessed based on changes in patient-reported
symptoms rather than serial stress tests or Holter
monitoring. However, as reported, the frequency of
sublingual nitroglycerin use is an indirect measure
of the overall angina burden, a composite that likely
reﬂects not just angina frequency and severity but
also its duration. Furthermore, we collected data for
several disease-speciﬁc and generic health status
measures (including results of a Seattle Angina
Questionnaire survey) prior to randomization and at
the end of treatment; these measures do capture
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421data for the overall angina burden and its impact on
patients’ quality of life. These analyses of the effect
of ranolazine on quality of life measures have been
completed, and recently published (2).
The third question is whether we observed a
glucose- and HBA1c-lowering effect of ranolazine
in TERISA. The objective of TERISA was to pros-
pectively assess the antianginal effectiveness of
ranolazine in patients with T2DM, not its potential
glucose-lowering effect. Therefore, although HBA1c
values were collected at baseline for cohort charac-
terization, no repeat measurements of HBA1c were
obtained following randomization, and no inference
with regard to ranolazine-mediated lowering of HBA1c
can be made from this clinical trial. Notably, an
extensive phase 3 drug development program to
assess the potential glycometabolic effects of ranola-
zine in a rigorously controlled fashion is currently
ongoing.*Mikhail Kosiborod, MD
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JAMA Intern Med 2014 Jun 2 [E-pub ahead of print].Resting Heart Rate
An Independent Predictor of
Congestive Heart FailureOpdahl et al. (1) recently reported some interesting
ﬁndings from the MESA (Multi-Ethnic Study of
Atherosclerosis) trial showing that elevated resting
heart rate (HR) was associated with increased risk for
incident heart failure (HF) during a 7-year follow-up.
Subjects in the top HR quartile had a more than
3-fold greater adjusted relative risk for incident HF
than subjects in the bottom HR quartile. The authors
are to be commended for their interesting analysis, but
when commenting on their ﬁndings, they did not take
into account the recent results of the VALUE (Valsar-
tan Antihypertensive Long-term Use Evaluation)
study (2) which made a more extensive analysis of the
HR–HF association in a larger sample (n ¼ 15,245 sub-
jects). Our analysis showed that both the baseline HR
and the HR values recorded after 1 year (in-trial HR)
were strong predictors of incident HF (2). In a multi-
variate Coxmodel, the hazard ratios for the highest HR
quintile were 2.48 (95% conﬁdence interval [CI]: 1.91
to 3.21) for baseline HR and 1.93 (95% CI: 1.45 to 2.55)
for in-trial HR, compared to the bottom HR quintile.
In their article, the MESA investigators claimed
that the association between elevated HR and inci-
dent HF may be explained by mechanisms other than
an underlying coronary artery disease because in
their study HR was not a predictor of coronary events
(1). However, this negative ﬁnding was probably due
to their study being underpowered to detect this
relationship because in the VALUE study we found
a signiﬁcant independent association between HR
and incident myocardial infarction (2). The hazard
ratios for the highest HR quintile were 1.48 (95%
CI: 1.15 to 1.90) for baseline HR and 1.38 (95% CI: 1.03
to 1.85) for in-trial HR.
As the MESA investigators stated in their article
(1), HR might not be a causative factor and the con-
nection between HR and HF could be explained by a
latent left ventricular dysfunction accompanied by a
compensatory increase in resting HR (3). To exclude
